Cre-controlled CRISPR: Conditional gene inactivation just got easier

To discover the function of a gene researchers turn it off and observe the consequences. Often genes have multiple functions that differ depending on a tissue and age. Some genes are essential to growth and turning them off too early can have profound consequences that can make observing other functions impossible. To avoid it, researchers have been using conditional gene inactivation which allows turning a gene off only in a specific tissue or later in development, e.g., in adulthood.

One of the systems used for conditional gene inactivation is Cre/lox. “It is the gold standard for the conditional gene inactivation in mice but over time has also become quite important in other model organisms such as zebrafish,” says Dr. Stefan Hans, researcher at the CRTD and author of the study. The Cre/lox system relies on an enzyme, known as Cre recombinase, and special sequences, known as lox. The lox sequences are inserted into the genome around the gene of interest.

Cre recognizes the lox sequences and removes the gene sandwiched between them. In such a way, the gene is turned off and will not be expressed in this cell. Over the years, the research community developed many lines of animals in which Cre recombinase is only present in a specific tissue. Using such Cre lines, it is possible to turn a gene off only in one tissue but not in the others.

Although commonly used, flanking a gene with lox sequences has its disadvantages. “Inactivating a specific gene takes a lot of time and effort. It requires sophisticated genome modifications and can take multiple generations of animals until the setup is ready for an experiment,” explains Dr. Hans. “Compared to the method we established, it is slow and very laborious,” he adds.

Cre-Controlled CRISPR, the new method developed by a team of Dresden researchers led by Prof. Michael Brand, combines the benefits of the Cre/lox system with the CRISPR/Cas9 genetic scissors. The CRISPR/Cas9 system is a relatively new method that quickly revolutionized life sciences and led to 2020 Nobel Prize in chemistry. Although simple to use in general, CRISPR/Cas9 is not easily limited to just one tissue, which means that adapting it to conditional gene inactivation takes time and effort.

“In Cre-Controlled CRISPR we are taking advantage of the tissue-specific expression of Cre and the ease of gene editing of CRISPR/Cas9,” says Dr. Hans. “By merging the two methods, we created a version of CRISPR/Cas9 that is switched on by a Cre recombinase. Using our method, researchers can still take advantage of vast libraries of already established animal lines that express Cre in different tissues. But Cre-Controlled CRISPR takes away the laborious genome editing because it removes the necessity to flank a gene with lox sequences. It actually requires adding only one sequence to the genome, no matter what the gene of interest is,” explains Dr. Hans. Without the need to sandwich a gene between the lox sequences, Cre-Controlled CRISPR is faster and easier.

The Cre-Controlled CRISPR is not only simpler to establish but, just as CRISPR/Cas9, it also offers the possibility to turn off multiple genes at a time. What is more, the CRTD researchers engineered their method to facilitate subsequent analyses of the cells were Cre-Controlled CRISPR was used. Once the CRISPR/Cas9 is turned on, the cells are labeled with a green fluorescent protein (GFP). Fluorescent proteins such as GFP are commonly used in life science and provide countless methods to separate the labeled cells from others to use them for further experiments, e.g., next generation sequencing or others.

“Although we developed Cre-Controlled CRISPR as a proof of concept in zebrafish, the method is versatile and should be applicable to other model organisms as well,” adds Dr. Hans.

###

Stefan Hans, Daniela Zöller, Juliane Hammer, Johanna Stucke, Sandra Spieß, Gokul Kesavan, Volker Kroehne, Juan Sebastian Eguiguren, Diana Ezhkova, Andreas Petzold, Andreas Dahl and Michael Brand: Cre-Controlled CRISPR mutagenesis provides fast and easy conditional gene inactivation in zebrafish. Nature Communications (February 2021)

The Center for Regenerative Therapies Dresden (CRTD) of TU Dresden is academic home for scientists from more than 30 nations. Their mission is to discover the principles of cell and tissue regeneration and leveraging this for recognition, treatment and reversal of diseases. The CRTD links the bench to the clinic, scientists to clinicians to pool expertise in stem cells, developmental biology, gene-editing and regeneration towards innovative therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, hematological diseases such as leukemia, metabolic diseases such as diabetes, retina and bone diseases.
Since 2016 the CRTD is part of the central scientific unit “Center for Molecular and Cellular Bioengineering” (CMCB) of the TU Dresden and plays a central role within the research priority area Health Sciences, Biomedicine, and Bioengineering of the TU Dresden.

Web: http://www.tu-dresden.de/cmcb/crtd

Web: http://www.tu-dresden.de/cmcb

The DcGC is a joint sequencing center of the Deep Sequencing Core Facility at the Center for Molecular and Cellular Bioengineering (CMCB) of the TU Dresden and the Sequencing Facility of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG). It is one of four DFG-funded German competence centers for next generation sequencing. The DcGC is an amalgamation of employees working at the CMCB, MPI-CBG, as well as Center for Systems Biology Dresden (CSBD). DcGC consists of three platforms focusing on long read sequencing technologies, single cell sequencing, and short read sequencing, covering the experimental workflows and the bioinformatic analysis.